In early February, the U.S. Federal Trade Commission published a proposed order that fines telehealth and discount prescription provider GoodRX $1.5 milllion. Though part of the case involves deception — one of two prongs under the FTC Act — the case also raises the first-of-its-kind use of the Health Breach Notification Rule. To help better understand the novel and complex issues embedded in the case, IAPP Editorial Director Jedidiah Bracy, CIPP, caught up with WilmerHale Partner Kirk Nahra, CIPP/US, to discuss some of the takeaways privacy pros in any industry vertical should consider.
Listen Here
10 Feb. 2023
Top takeaways from the FTC-GoodRx case: A chat with Kirk Nahra
Related stories
Notes from the IAPP Canada: Regulators should better understand data breach complexities
Ontario's IPC works toward balancing youth safeguards, empowerment
A view from DC: Pride, coded language and the tragic irony of a private life
UK Parliament advances Data (Use and Access) Bill, awaits Royal Assent
A view from Brussels: Is Europe ramping up its agenda on protecting children online?
This article is eligible for Continuing Professional Education credits. Please self-submit according to CPE policy guidelines.